Gold bars to be exempt from tariffs, White House clarifies
MCKINNEY, Texas - Globe Life Inc. (NYSE:GL), a financial services company with a market capitalization of $11.66 billion, announced Thursday that its Board of Directors has declared a quarterly dividend of $0.2700 per share on all outstanding common stock of the company. According to InvestingPro data, the company has maintained dividend payments for 55 consecutive years, with a current annual dividend yield of 0.76%.
The dividend will be paid on October 31, 2025, to shareholders of record as of the close of business on October 3, 2025.
Globe Life, headquartered in McKinney, Texas, operates as a holding company specializing in life and supplemental health insurance products targeted at the middle-income market. The company distributes its insurance products through multiple channels, including direct-to-consumer sales and exclusive and independent agencies.
The announcement was made in a company press release statement issued Thursday. The company maintains a "GREAT" overall financial health score of 3.2 out of 4 on InvestingPro’s comprehensive assessment system, which evaluates multiple financial metrics and performance indicators.
In other recent news, Globe Life has seen a series of developments following the closure of investigations by both the Securities and Exchange Commission and the Department of Justice into its sales practices. The conclusion of these investigations, which involved no enforcement action, has removed significant regulatory uncertainty for the company. Morgan Stanley responded by upgrading Globe Life’s stock rating from Equalweight to Overweight and increasing its price target from $135.00 to $166.00. Meanwhile, BMO Capital raised its price target for the company to $149.00, citing potential improvements in free cash flow and price-to-earnings metrics. Additionally, TD Cowen maintained its Buy rating with a price target of $182.00, aligning with the positive outlook following the DOJ’s conclusion. Keefe, Bruyette & Woods also adjusted their price target upward to $160.00, maintaining an Outperform rating. These analyst actions reflect a more optimistic view of Globe Life’s financial prospects in light of the resolved regulatory issues.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.